Antibiotic Resistance Research Report 2024: 6 Key Large Opportunities in this Space and Developed Market Forecasts with Profiles of 100+ Biotechnology Companies
15. Oktober 2024 10:31 ET
|
Research and Markets
Dublin, Oct. 15, 2024 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides &...
Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024
14. Oktober 2024 07:31 ET
|
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals Announces Presentation of Several New Studies of NUZYRA® (omadacycline) Across a Range of Serious Infections at IDWeek 2024
Inbiome Receives FDA Breakthrough Device Designation for Revolutionary Molecular Culture ID Technology, Transforming Bacterial Diagnostics
26. September 2024 04:03 ET
|
inbiome
www.inbiome.com More precise diagnostics lead to quicker, more accurate patient treatment, saving lives and improving patient outcomesUS market introduction foreseen early 2026 ...
Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency Against Indicated Pathogens
31. Juli 2024 07:30 ET
|
Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline)
Antimicrobial Resistance Surveillance Market Size to Hit US$ 9.50 Billion by 2032, Rising Prevalence of Drug-Resistant Infections Drives Growth | Research by SNS Insider
22. Juli 2024 13:47 ET
|
SNS Insider pvt ltd
Pune, July 22, 2024 (GLOBE NEWSWIRE) -- Antimicrobial Resistance Surveillance Market Size Analysis: “According to SNS Insider Research, The Antimicrobial Resistance Surveillance Market is...
$230+ Bn Anti-Infectives Markets - Global Strategic Business Report to 2030: Telemedicine and Digital Health Platforms Drives Adoption, Rising Prevalence of Drug-Resistant Infections Spurs Innovation
22. Juli 2024 09:15 ET
|
Research and Markets
Dublin, July 22, 2024 (GLOBE NEWSWIRE) -- The "Anti-Infectives - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for Anti-Infectives...
AUROBAC THERAPEUTICS APPOINTS SCIENTIFIC ADVISORY BOARD
20. Juni 2024 08:00 ET
|
AUROBAC THERAPEUTICS
The newly formed Scientific Advisory Board chaired by Dr. Marco Taglietti will provide technical and strategic guidance to support AUROBAC’s R&D strategy. Lyon (France), June 20, 2024 ...
AUROBAC THERAPEUTICS Presents its R&D Strategy & Pipeline and Announces New Development Program in Partnership with Boehringer Ingelheim
03. Juni 2024 08:14 ET
|
AUROBAC THERAPEUTICS
AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens. Lyon (France), June 3, 2024 AUROBAC THERAPEUTICS, a...
Antibiotic Resistance Markets Therapeutics, by Pathogen and Therapy Type to 2027: Search for Alternatives to Antibiotics Creates New Global Goldrush
27. Mai 2024 03:01 ET
|
Research and Markets
Dublin, May 27, 2024 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics by Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides & Customization....
Global Cephalosporin Drug Market Report 2024 Insights and Forecasts 2019-2022 and 2023-2029 - The Role of Advanced Cephalosporin Formulations, New Generations and Combination Therapies in Development
22. Februar 2024 06:16 ET
|
Research and Markets
Dublin, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The "Global Cephalosporin Drug Market (2024 Edition): Analysis by Generation, Route of Administration, Application (Respiratory Tract Infection, Skin...